Earnings Report
Earnings Report: second quarter 2026
Other upcoming events for AGIO
Phase 3 ReadoutPhase 3 Topline: An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanc
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy a
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy a
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.